---
title: "Imlifidase: Kidney transplantation in highly sensitized patients"
description: "Formulary evidence on Imlifidase in Kidney transplantation in highly sensitized patients. Clinical evidence covers ConfIdeS, Highdes, 13-HMedIdeS-03, 14-HMedIdeS-04, 20-HMedIdeS-19, 17-HMedIdeS-14, and 11 further headings. 254 evidence topics quoted from 84 sources. Every quote links to the document it came from."
canonical: "https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Imlifidase: Kidney transplantation in highly sensitized patients

<a id="executive-summary"></a>

## 1 Executive Summary

<a id="heading-1.1"></a>

### 1.1 Clinical Benefits of Imlifidase

<a id="heading-1.1.1"></a>

#### 1.1.1 Burden of Kidney transplantation in highly sensitized patients

<a id="topic-1.1.1-1"></a>

##### Summary

Sensitization can follow pregnancy, blood transfusion, tissue grafting, or previous transplantation. Highly sensitized candidates are reported to comprise approximately 10–15% of transplant waiting lists across the United States and Europe. A United States allocation analysis found that candidates with CPRA of at least 99.9% continued to have lower transplant rates than the overall average despite national priority. Kidney failure affects daily activities, and in-center hemodialysis commonly requires three sessions per week, each lasting approximately four hours.

Source: [HRSA Organ Procurement and Transplantation Network](https://www.hrsa.gov/optn/policies-bylaws/public-comment/remove-cpra-99-100-form-highly-sensitized-kidney-candidates); [Hansa Biopharma ConfIdeS ATC 2026 plenary abstract announcement (2026)](https://www.hansabiopharma.com/media/press-releases/2026/hansa-biopharma-announces-confides-phase-3-abstract-selected-for-whats-hot-whats-new-plenary-at-atc-2026/); [Maldonado et al. (2021)](https://www.lidsen.com/journals/transplantation/transplantation-05-02-143); [National Institute of Diabetes and Digestive and Kidney Diseases](https://www.niddk.nih.gov/health-information/kidney-disease/kidney-failure/what-is-kidney-failure); [National Institute of Diabetes and Digestive and Kidney Diseases (2018)](https://www.niddk.nih.gov/health-information/kidney-disease/kidney-failure/hemodialysis)

<a id="heading-1.1.2"></a>

#### 1.1.2 Imlifidase Efficacy and Safety

<a id="topic-1.1.2-1"></a>

##### Summary

ConfIdeS was an open-label, randomized, controlled phase 3 trial involving 64 participants with cPRA of at least 99.9%. The sponsor reported mean eGFR at 12 months of 51.5 mL/min/1.73 m² with imlifidase and 19.3 mL/min/1.73 m² in the control arm, with p<0.0001. A subsequent sponsor presentation reported antibody-mediated rejection in 16 of 28 participants in the imlifidase arm and 6 of 13 in the control arm. These rejection denominators are not the full randomized population. The UK product information reports pneumonia in 5.6% and sepsis in 3.7% as the most common serious adverse reactions in the clinical studies supporting that document.

Source: [Hansa Biopharma BLA acceptance announcement (2026)](https://www.hansabiopharma.com/media/press-releases/2026/hansa-biopharmas-biologics-license-application-bla-for-imlifidase-accepted-by-the-fda/); [Hansa Biopharma ConfIdeS primary endpoint announcement (2025)](https://www.hansabiopharma.com/media/press-releases/2025/imlifidase-successfully-meets-primary-endpoint-in-pivotal-us-phase-3-confides-trial-in-kidney-transplantation/); [Hansa Biopharma capital markets presentation (2026)](https://www.hansabiopharma.com/files/Presentations/2026/capital-markets-jun-25-2026--for-external-use.pdf); [Idefirix UK Summary of Product Characteristics](https://www.medicines.org.uk/emc/product/13155/smpc)

<a id="heading-1.1.3"></a>

#### 1.1.3 Budget Impact of Imlifidase

<a id="topic-1.1.3-1"></a>

##### Summary

The Irish NCPE assessment includes a five-year budget-impact analysis, distinct from its lifetime cost-effectiveness model. The budget analysis assumed approximately 20 eligible patients and four to five imlifidase-enabled transplants annually. It estimated gross drug expenditure of €8,721,695 and a net total budget impact of €5,376,092 after other healthcare costs and dialysis cost offsets. These estimates describe the Irish population, prices, and model assumptions, not a United States budget impact.

Source: [NCPE (2024)](https://www.ncpe.ie/wp-content/uploads/2024/11/Imlifidase-Technical-Summary-23041.pdf)

<a id="heading-1.1.4"></a>

#### 1.1.4 Conclusions

<a id="topic-1.1.4-1"></a>

##### Summary

Imlifidase has a conditional European authorization for selected highly sensitized adult kidney transplant candidates with a positive crossmatch against an available deceased donor. The United States BLA was accepted, with an announced FDA action date of December 19, 2026; the cited notice is not an approval. Treatment requires confirmation of crossmatch conversion, concomitant immunosuppression, and monitoring for rejection and infection. The randomized ConfIdeS results support improved 12-month kidney function in the studied population, but the reported rejection events and infection risks remain relevant to treatment selection and follow-up. Economic findings should be interpreted separately by jurisdiction and by model type.

Source: [European Medicines Agency Idefirix EPAR](https://www.ema.europa.eu/en/medicines/human/EPAR/idefirix); [Hansa Biopharma regulatory status page](https://www.hansabiopharma.com/our-science/regulatory-status/); [Hansa Biopharma BLA acceptance announcement (2026)](https://www.hansabiopharma.com/media/press-releases/2026/hansa-biopharmas-biologics-license-application-bla-for-imlifidase-accepted-by-the-fda/); [Hansa Biopharma PDUFA action date announcement (2026)](https://www.hansabiopharma.com/media/press-releases/2026/pdufa-action-date-for-hansa-biopharmas-imlifidase-bla-set-for-december-19-2026/); [Furian et al. (2025)](https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2024.13886/full); [Couzi et al. (2023)](https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2023.11244/full); [Hansa Biopharma ConfIdeS primary endpoint announcement (2025)](https://www.hansabiopharma.com/media/press-releases/2025/imlifidase-successfully-meets-primary-endpoint-in-pivotal-us-phase-3-confides-trial-in-kidney-transplantation/); [Hansa Biopharma capital markets presentation (2026)](https://www.hansabiopharma.com/files/Presentations/2026/capital-markets-jun-25-2026--for-external-use.pdf); [Idefirix UK Summary of Product Characteristics](https://www.medicines.org.uk/emc/product/13155/smpc); [NCPE (2024)](https://www.ncpe.ie/wp-content/uploads/2024/11/Imlifidase-Technical-Summary-23041.pdf)

## Related pages
- [Imlifidase in Kidney transplantation in highly sensitized patients: Terms and abbreviations](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/terms-and-abbreviations.md)
- [Imlifidase: Kidney transplantation in highly sensitized patients](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/executive-summary) · [Markdown](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/executive-summary.md)
- [Imlifidase in Kidney transplantation in highly sensitized patients: Product information and disease description](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/product-information-and-disease-description.md)
- [Imlifidase in Kidney transplantation in highly sensitized patients: Clinical evidence](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/clinical-evidence.md)
- [Imlifidase in Kidney transplantation in highly sensitized patients: Economic information and modeling report](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/economics) · [Markdown](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/economics.md)
- [Imlifidase in Kidney transplantation in highly sensitized patients: References](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/references) · [Markdown](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/references.md)
- [Imlifidase in Kidney transplantation in highly sensitized patients: prevalence by geography](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/prevalence) · [Markdown](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/prevalence.md)
- [Imlifidase in Kidney transplantation in highly sensitized patients: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/cost-effectiveness-analyses.md)
